Related Experiment Video
Updated: Aug 14, 2026
12:08
Diagonal Method to Measure Synergy Among Any Number of Drugs
Published on: June 21, 2018
Multiple comparisons in drug efficacy studies: scientific or marketing principles?
1Lake Erie College of Osteopathic Medicine, Florida, USA.
Ethical Human Psychology and Psychiatry
|February 15, 2005
Summary
This article examines how clinical trial data, like that for celecoxib (Celebrex) and the Multimodal Treatment Study (MTA), can be selectively reported to favor drug marketing over scientific integrity.
Area of Science:
- Clinical Trial Design and Analysis
- Pharmaceutical Marketing Ethics
- Evidence-Based Medicine
Background:
- Clinical trials often involve multiple comparisons (e.g., different methods, raters, time points) for scientific rigor.
- These complex comparisons present opportunities for selective reporting, potentially influenced by marketing interests.
- Concerns arise when study designs and data presentation may obscure or misrepresent actual findings.
Discussion:
- Examines the selective presentation of data in the celecoxib (Celebrex) arthritis drug trial, where only 6 months of a 12-month study were reported.
- Discusses the National Institute of Mental Health (NIMH) Multimodal Treatment Study (MTA) for attention-deficit hyperactivity disorder (ADHD), noting contradictory findings and lack of clarification.
Key Insights:
- Selective data reporting can obscure actual study outcomes, potentially misleading healthcare professionals and the public.
- Ambiguities in reporting, as seen in the MTA study, raise concerns about the influence of conclusions over empirical findings.
Outlook:
- Calls for greater transparency and rigorous scrutiny of clinical trial reporting to prevent marketing abuses.
- Emphasizes the importance of clear, comprehensive data presentation to uphold scientific standards and public trust in medical research.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
11:15Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
Published on: July 24, 2021
Related Concept Videos
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:22Dose-Response Relationship: Potency and Efficacy
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
01:16Bioequivalence Data: Statistical Interpretation
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...